Skip to main content
. Author manuscript; available in PMC: 2023 Feb 3.
Published in final edited form as: Mol Cancer Res. 2023 Feb 1;21(2):170–186. doi: 10.1158/1541-7786.MCR-22-0486

Figure 1. TWEAK activates classical and alternative NF-κB pathways in ovarian cancer cell lines and patient-derived cells.

Figure 1.

(A) Luciferase reporter assay showing NF-κB activity in response to 24 hour stimulation with different cytokines (n=3). (B) DNA-binding of NF-κB proteins with TWEAK stimulation (25ng/ml) for 2 or 24 hours relative to vehicle. One-way ANOVA with Dunnett’s post-hoc (n=3). (C) Nuclear and Cytosolic western blots of NF-κB proteins with TWEAK (25ng/ml, 0, 2, or 24 hours) in CAOV4, OVCAR8, and OV90. (D) Nuclear and Cytosolic western blots of NF-κB proteins with TWEAK (100ng/ml, 24 hours) stimulation in ascites sample VBCF004. Data represent mean and SEM. * p<0.05.